FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
| Autor: | Loupakis, F., Cremolini, C., Salvatore, L., Masi, G., Sensi, E., Schirripa, M., Michelucci, A., Pfanner, E., Brunetti, I., Lupi, C., Antoniotti, C., Bergamo, F., Lonardi, S., Zagonel, V., Simi, P., Fontanini, G., Falcone, A. |
|---|---|
| Zdroj: | In European Journal of Cancer January 2014 50(1):57-63 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect